Keywords: basilsea, reports, positive, data, ceftobiprole, trials, switzerland-based
Basilsea reports positive data from ceftobiprole trials
Article | 09 January 2006
Switzerland-based Basilea Pharmaceutica says that its broad-spectrum antibiotic ceftobiprole, which it is developing in partnership with Johnson & Johnson, has potent ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
